What is the recommended testing protocol for chlamydia and gonorrhea?

Testing for Chlamydia and Gonorrhea

Screen all sexually active women aged 24 years or younger annually for both chlamydia and gonorrhea, and screen women 25 years or older who have risk factors for infection. 1

Screening Recommendations by Population

Women

• All sexually active women ≤24 years: Annual screening for both chlamydia and gonorrhea 2, 1
• Women ≥25 years with risk factors: Screen for both infections 2, 1
  • Risk factors include: new or multiple sex partners, partner with concurrent partners, previous STI, inconsistent condom use, commercial sex work, or illicit drug use 2

Men

The evidence remains insufficient to recommend routine screening in heterosexual men 1. However, consider screening in specific circumstances:

• Men who have sex with men (MSM): Annual screening at minimum, with testing every 3-6 months for those at highest risk (multiple/anonymous partners, drug use during sex) 2
  • Screen at all exposed anatomic sites based on sexual practices:
    • Urethral specimens for insertive intercourse
    • Rectal specimens for receptive anal intercourse
    • Pharyngeal specimens for receptive oral sex 2
• High-prevalence settings: Consider screening sexually active young men in jails, juvenile detention, STD clinics, and adolescent clinics 2

Pregnant Women

• Chlamydia: Screen all pregnant women at first prenatal visit 2
• Gonorrhea: Screen high-risk pregnant women at first prenatal visit 2
• Retest in third trimester if initial test positive or continued risk factors present 2

Testing Methods

Nucleic acid amplification tests (NAATs) are the gold standard for detecting both infections due to superior sensitivity and specificity compared to all other available tests 3. NAATs should be used in all cases except:

• Child sexual assault involving boys
• Rectal/oropharyngeal infections in prepubescent girls
• Suspected gonorrhea treatment failure requiring culture and susceptibility testing 3

Specimen Types

• First-void urine and vaginal swabs (clinician or self-collected) have FDA clearance and excellent performance 4
• Self-collected vaginal swabs show sensitivity >90% and specificity >98%, comparable to clinician-collected specimens 4
• Extragenital specimens (rectal, pharyngeal) increasingly important for MSM and women with relevant exposures, though FDA clearance for self-collection at these sites is still pending 5, 4

Screening Intervals

• Standard risk populations: Annual screening 2
• MSM at high risk: Every 3-6 months 2
• After positive test and treatment: Retest at 3 months due to high reinfection rates, regardless of partner treatment status 2
• Emerging guidance: Some experts suggest universal screening every 3-6 months for those with multiple/new partners, with "opt-out" screening as frequently as every 3 months in high-prevalence communities 6

Critical Pitfalls to Avoid

1. Don't skip extragenital screening in MSM: Infections at pharyngeal and rectal sites are frequently asymptomatic and missed if only urethral specimens obtained 2

2. Don't forget the 3-month retest: Reinfection rates are high enough to warrant routine retesting after treatment, even when partners report being treated 2

3. Don't use NAATs alone in treatment failure: Gonorrhea treatment failures require culture with susceptibility testing to guide management and monitor resistance 3

4. Don't overlook pregnant women: Universal chlamydia screening and risk-based gonorrhea screening at first prenatal visit prevents serious neonatal complications 2

5. Consider community prevalence for syphilis co-screening: In areas with primary/secondary syphilis rates >4.6 per 100,000, offer concurrent syphilis screening given epidemiologic overlap 5

The USPSTF gives these recommendations a B grade (moderate certainty of moderate net benefit) for women, reflecting strong evidence that screening prevents pelvic inflammatory disease, infertility, ectopic pregnancy, and neonatal transmission 1. The lack of recommendation for routine screening in heterosexual men reflects insufficient evidence of benefit, not evidence of no benefit 1.